Non-hematopoietic EPO-derived peptide for neuropathic pain and tissue protection.
TL;DR — ARA-290 is a recovery & repair peptide with a typical starting dose of 4 mg. For a 16 mg vial, add 1 mL bacteriostatic water to yield 16 mg/mL.
Add 1 mL of bacteriostatic water to a 16 mg vial, injecting slowly down the inside wall. Swirl gently; never shake. This yields a concentration of 16 mg/mL.
What is the recommended dose of ARA-290?
A typical research dose is 4 mg. Consult the ASCEND calculator for your specific vial concentration and draw volume.
How many doses are in a ARA-290 vial?
A 16 mg vial reconstituted with 1 mL BAC water yields approximately 4 doses at 4 mg each.
Peptide Intelligence
What is ARA-290 and how does it work?
ARA-290 is an 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and beta common receptor. Unlike EPO, it has no hematopoietic activity and does not affect red blood cell production.
What is the half-life of ARA-290?
ARA-290 has a short half-life of approximately 2–4 hours, necessitating daily subcutaneous injections in research protocols. It does not bind the classical EPO receptor homodimer, carrying no thromboembolic risk associated with EPO itself.
What neuropathy applications is ARA-290 researched for?
ARA-290 has been studied for small fiber neuropathy, diabetic peripheral neuropathy, and sarcoidosis-associated neuropathy. Clinical trials have shown reduction in neuropathic pain scores and improvement in corneal nerve fiber density over treatment periods.